Key Points
- Royalty Pharma EVP Marshall Urist sold 9,099 shares on July 1 at an average price of $55.88, for a total of about $508,452. The trade was made under a pre-arranged Rule 10b5-1 plan.
- This was part of a recent pattern of insider selling, with Urist also selling shares on June 24, May 20, and May 14.
- Royalty Pharma’s stock is near its 52-week high, recently trading at $57.77 after a 3.6% gain, while analysts remain broadly positive with an average Buy rating and a consensus target price of $53.71.
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 9,099 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total transaction of $508,452.12. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Marshall Urist also recently made the following trade(s):
- On Wednesday, June 24th, Marshall Urist sold 9,098 shares of Royalty Pharma stock. The shares were sold at an average price of $55.18, for a total transaction of $502,027.64.
- On Wednesday, May 20th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The stock was sold at an average price of $52.75, for a total value of $721,831.00.
- On Thursday, May 14th, Marshall Urist sold 13,684 shares of Royalty Pharma stock. The stock was sold at an average price of $53.06, for a total value of $726,073.04.
Royalty Pharma Stock Up 3.6%
RPRX stock opened at $57.77 on Friday. The stock has a market capitalization of $33.27 billion, a P/E ratio of 39.30, a P/E/G ratio of 1.53 and a beta of 0.43. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.66 and a quick ratio of 2.66. Royalty Pharma PLC has a 1-year low of $34.08 and a 1-year high of $57.80. The business has a fifty day moving average price of $53.40 and a 200-day moving average price of $47.16.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The company had revenue of $630.58 million for the quarter, compared to analysts' expectations of $881.69 million. Equities analysts forecast that Royalty Pharma PLC will post 5.05 earnings per share for the current fiscal year.
Royalty Pharma Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were paid a dividend of $0.235 per share. The ex-dividend date was Friday, May 15th. This represents a $0.94 annualized dividend and a yield of 1.6%. Royalty Pharma's dividend payout ratio is currently 63.95%.
Hedge Funds Weigh In On Royalty Pharma
A number of institutional investors have recently bought and sold shares of the stock. Phillips Wealth Planners LLC lifted its stake in shares of Royalty Pharma by 1.9% during the fourth quarter. Phillips Wealth Planners LLC now owns 13,113 shares of the biopharmaceutical company's stock worth $521,000 after buying an additional 242 shares during the period. Strs Ohio increased its position in shares of Royalty Pharma by 2.8% in the 4th quarter. Strs Ohio now owns 9,318 shares of the biopharmaceutical company's stock valued at $360,000 after acquiring an additional 252 shares during the period. Glenmede Trust Co. NA increased its position in shares of Royalty Pharma by 3.4% in the 1st quarter. Glenmede Trust Co. NA now owns 7,812 shares of the biopharmaceutical company's stock valued at $375,000 after acquiring an additional 254 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Royalty Pharma by 0.6% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 43,287 shares of the biopharmaceutical company's stock worth $1,673,000 after acquiring an additional 255 shares during the last quarter. Finally, Cary Street Partners Financial LLC raised its stake in Royalty Pharma by 1.1% in the 4th quarter. Cary Street Partners Financial LLC now owns 24,405 shares of the biopharmaceutical company's stock worth $943,000 after acquiring an additional 260 shares during the last quarter. 54.35% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on RPRX. Weiss Ratings lowered shares of Royalty Pharma from a "buy (b)" rating to a "buy (b-)" rating in a research note on Friday, May 15th. JPMorgan Chase & Co. raised their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an "overweight" rating in a report on Thursday, May 7th. UBS Group lifted their target price on shares of Royalty Pharma from $51.00 to $57.00 and gave the stock a "buy" rating in a research report on Tuesday, April 21st. Morgan Stanley lifted their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a research report on Friday, April 10th. Finally, Citigroup increased their price target on Royalty Pharma from $50.00 to $66.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $53.71.
View Our Latest Research Report on RPRX
About Royalty Pharma
(
Get Free Report)
Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.
The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
